Expression of Concern
This article is currently under investigation. We strongly recommend that this article is not cited until the investigation is completed.
This article is currently under investigation. We strongly recommend that this article is not cited until the investigation is completed.
Research Paper Volume 12, Issue 11 pp 11025—11041
LncRNA ADAMTS9-AS2 inhibits gastric cancer (GC) development and sensitizes chemoresistant GC cells to cisplatin by regulating miR-223-3p/NLRP3 axis
Figure 4. The expression patterns of LncRNA ADAMTS9-AS2 and miR-223-3p were changed by long-term cisplatin stimulation in GC cells. Real-Time qPCR was used to examine the expression levels of (A) LncRNA ADAMTS9-AS2 and (B) miR-223-3p in CS-GC and CR-GC cells. (C) The schematic diagram for the production of ACR-GC cells involved in this study. (D) Trypan blue staining assay was performed to evaluate cell viability in CS-GC cells and ACR-GC cells. Real-Time qPCR was conducted to examine the expression levels of (E) LncRNA ADAMTS9-AS2 and (F) miR-223-3p in GC cells treated with continuous low-dose cisplatin stimulation. Each experiment repeated at least 3 times. “NS” represented “no statistical significance”, *P < 0.05, **P < 0.01.